Beyond PD-L1, several other biomarkers have been identified and used to profile patient prediction, including tumor mutational burden (TMB) [8], tumor microenvironment (TME) [9], microRNA (miRNA) [10], immune gene signatures [11], gut microbiome [12], radiomics [13], and baseline clinical features or their combination in different scores [14,15]. This evidence concerns the gene CD274 and neoplasm.